The effect of combined IL10 siRNA and CpG ODN as pathogen-mimicking microparticles on Th1/Th2 cytokine balance in dendritic cells and protective immunity against B cell lymphoma

Biomaterials

Volumn 35, Issue 21, 2014, Pages 5491-5504

  Pradhan, Pallab ^a,c   Qin, Hong ^b   Leleux, Jardin A ^a,c   Gwak, Dongho ^b   Sakamaki, Ippei ^b   Kwak, Larry W ^b   Roy, Krishnendu ^a,c  

^a GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c The University of Texas at Austin   (United States)

Author keywords

Cancer; CpG; Immunotherapy; Lymphoma; Microparticle; SiRNA

Indexed keywords

CELLS; DISEASES; OLIGONUCLEOTIDES; ONCOLOGY; VACCINES;

CANCER; CPG; IMMUNOTHERAPY; LYMPHOMA; MICRO PARTICLES; SIRNA;

T-CELLS;

ANTINEOPLASTIC AGENT; CPG-OLIGONUCLEOTIDE; INTERLEUKIN 10; OLIGODEOXYRIBONUCLEOTIDE; POLYINOSINIC POLYCYTIDYLIC ACID; SMALL INTERFERING RNA; TLR3 PROTEIN, MOUSE; TLR9 PROTEIN, MOUSE; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 9;

AGONISTS; ANIMAL; B CELL LYMPHOMA; BAGG ALBINO MOUSE; BIOMIMETICS; CELL CULTURE; CHEMISTRY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; IMMUNOLOGY; IMMUNOTHERAPY; MEMBRANE MICROPARTICLE; MESENCHYMAL STROMA CELL; METABOLISM; MOUSE; PROCEDURES; TH1 TH2 BALANCE;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOMIMETICS; CELL-DERIVED MICROPARTICLES; CELLS, CULTURED; DENDRITIC CELLS; IMMUNOTHERAPY; INTERLEUKIN-10; LYMPHOMA, B-CELL; MESENCHYMAL STROMAL CELLS; MICE; MICE, INBRED BALB C; OLIGODEOXYRIBONUCLEOTIDES; POLY I-C; RNA, SMALL INTERFERING; T-LYMPHOCYTES, CYTOTOXIC; TH1-TH2 BALANCE; TOLL-LIKE RECEPTOR 3; TOLL-LIKE RECEPTOR 9;

EID: 84899489828     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.03.039     Document Type: Article

References (33)

1. Steinman R.M., Cohn Z.A. Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. JExp Med 1973, 137:1142-1162.
2. Reis e Sousa C. Activation of dendritic cells: translating innate into adaptive immunity. Curr Opin Immunol 2004, 16:21-25.
3. Steinman R.M., Hemmi H. Dendritic cells: translating innate to adaptive immunity. Curr Top Microbiol Immunol 2006, 311:17-58.
4. Medzhitov R. Toll-like receptors and innate immunity. Nat Rev Immunol 2001, 1:135-145.
5. Palucka K., Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer 2012, 12:265-277.
6. Huang H., Hao S.G., Li F., Ye Z.M., Yang J.B., Xiang J. CD4(+) Th1 cells promote CD8(+) Tc1 cell survival, memory response, tumor localization and therapy by targeted delivery of interleukin 2 via acquired pMHC I complexes. Immunology 2007, 120:148-159.
7. Knutson K.L., Disis M.L. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol Immunother 2005, 54:721-728.
8. Akira S., Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004, 4:499-511.
9. Krieg A.M. Development of TLR9 agonists for cancer therapy. JClin Invest 2007, 117:1184-1194.
10. Bode C., Zhao G., Steinhagen F., Kinjo T., Klinman D.M. CpG DNA as a vaccine adjuvant. Expert Rev Vaccine 2011, 10:499-511.
11. Salem M.L., Kadima A.N., Cole D.J., Gillanders W.E. Defining the antigen-specific T-cell response to vaccination and poly(I: C)/TLR3 signaling: evidence of enhanced primary and memory CD8 T-cell responses and antitumor immunity. JImmunother 2005, 28:220-228.
12. Currie A.J., van der Most R.G., Broomfield S.A., Prosser A.C., Tovey M.G., Robinson B.W. Targeting the effector site with IFN-alphabeta-inducing TLR ligands reactivates tumor-resident CD8 T cell responses to eradicate established solid tumors. JImmunol 2008, 180:1535-1544.
13. Krummen M., Balkow S., Shen L.M., Heinz S., Loquai C., Probst H.C., et al. Release of IL-12 by dendritic cells activated by TLR ligation is dependent on MyD88 signaling, whereas TRIF signaling is indispensable for TLR synergy. JLeukoc Biol 2010, 88:189-199.
14. Zheng R.X., Cohen P.A., Paustian C.A., Johnson T.D., Lee W.T., Shu S.Y., et al. Paired toll-like receptor agonists enhance vaccine therapy through induction of interleukin-12. Cancer Res 2008, 68:4045-4049.
15. Napolitani G., Rinaldi A., Bertoni F., Sallusto F., Lanzavecchia A. Selected toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat Immunol 2005, 6:769-776.
16. Pashenkov M., Goess G., Wagner C., Hormann M., Jandl T., Moser A., et al. Phase II trial of a toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma. JClin Oncol 2006, 24:5716-5724.
17. Friedberg J.W., Kim H., McCauley M., Hessel E.M., Sims P., Fisher D.C., et al. Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-alpha/beta-inducible gene expression, without significant toxicity. Blood 2005, 105:489-495.
18. Dearman R.J., Cumberbatch M., Maxwell G., Basketter D.A., Kimber I. Toll-like receptor ligand activation of murine bone marrow-derived dendritic cells. Immunology 2009, 126:475-484.
19. Corinti S., Albanesi C., la Sala A., Pastore S., Girolomoni G. Regulatory activity of autocrine IL-10 on dendritic cell functions. JImmunol 2001, 166:4312-4318.
20. Saraiva M., O'garra A. The regulation of IL-10 production by immune cells. Nat Rev Immunol 2010, 10:170-181.
21. Asadullah K., Sterry W., Volk H.D. Interleukin-10 therapy-review of a new approach. Pharmacol Rev 2003, 55:241-269.
22. Liu G., Ng H., Akasaki Y., Yuan X., Ehtesham M., Yin D., et al. Small interference RNA modulation of IL-10 in human monocyte-derived dendritic cells enhances the Th1 response. Eur J Immunol 2004, 34:1680-1687.
23. Chhabra A., Chakraborty N.G., Mukherji B. Silencing of endogenous IL-10 in human dendritic cells leads to the generation of an improved CTL response against human melanoma associated antigenic epitope, MART-1 27-35. Clin Immunol 2008, 126:251-259.
24. Singh A., Qin H., Fernandez I., Wei J., Lin J., Kwak L.W., et al. An injectable synthetic immune-priming center mediates efficient T-cell class switching and T-helper 1 response against B cell lymphoma. JControl Release 2011, 155:184-192.
25. Singh A., Nie H., Ghosn B., Qin H., Kwak L.W., Roy K. Efficient modulation of T-cell response by dual-mode, single-carrier delivery of cytokine-targeted siRNA and DNA vaccine to antigen-presenting cells. Mol Ther 2008, 16:2011-2021.
26. Qin H., Cha S.C., Neelapu S.S., Lou Y., Wei J., Liu Y.J., et al. Vaccine site inflammation potentiates idiotype DNA vaccine-induced therapeutic T cell-, and not B cell-, dependent antilymphoma immunity. Blood 2009, 114:4142-4149.
27. Kasturi S.P., Sachaphibulkij K., Roy K. Covalent conjugation of polyethyleneimine on biodegradable microparticles for delivery of plasmid DNA vaccines. Biomaterials 2005, 26:6375-6385.
28. Pai Kasturi S., Qin H., Thomson K.S., El-Bereir S., Cha S.C., Neelapu S., et al. Prophylactic anti-tumor effects in a B cell lymphoma model with DNA vaccines delivered on polyethylenimine (PEI) functionalized PLGA microparticles. JControl Release 2006, 113:261-270.
29. Inaba K., Inaba M., Romani N., Aya H., Deguchi M., Ikehara S., et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. JExp Med 1992, 176:1693-1702.
30. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25:402-408.
31. Singh A., Suri S., Roy K. In-situ crosslinking hydrogels for combinatorial delivery of chemokines and siRNA-DNA carrying microparticles to dendritic cells. Biomaterials 2009, 30:5187-5200.
32. Biragyn A., Tani K., Grimm M.C., Weeks S., Kwak L.W. Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity. Nat Biotechnol 1999, 17:253-258.
33. Vanneman M., Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer 2012, 12:237-251.